Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Non-Thermal heart ablation shows promise for persistent AF

NCT ID NCT06985901

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new procedure called pulsed-field ablation to treat persistent atrial fibrillation, a common heart rhythm problem. The procedure uses non-thermal energy to isolate the pulmonary veins, aiming to stop abnormal heart signals. Researchers will follow 60 participants for 12 months using an implantable heart monitor to check if the procedure prevents arrhythmia recurrences.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulsed-field ablation (a non-thermal energy procedure)
What this could lead to
If successful, this could provide a safer, more effective way to treat persistent atrial fibrillation, reducing the need for long-term medication.
What could go wrong
This is a small, early pilot study with only 60 participants, so results may not apply to everyone. The procedure carries risks like bleeding, infection, or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic persistent AF (continuous episode sustained beyond 7 days) * Refractory, intolerant or unwilling to take ADT * Signed informed consent * Affiliation to medical social coverage. Non inclusion Criteria: * Persistent long-term atrial fibrillation with ongoing episode continuous for more than 3 years; * Left ventricular ejection fraction ≤ 15% ; * Stage IV of the New York Heart Association classification; * Previous atrial ablation outside the cavotricuspid isthmus; * Wearer of an implantable electronic cardiac prosthesis (pacemaker or defibrillator; MCI) * Hypertrophic heart disease other than hypertensive hypertrophic heart disease; * Severe valvular heart disease, including the presence of a mechanical mitral valve or any mitral surgery; * Congenital heart disease, including atrial septal defect, patent foramen ovale treated by percutaneous closure with atrial septal prosthesis; * Presence of cardiac thrombus; * Myocardial infarction or percutaneous coronary angioplasty within the last 6 months; * Cardiac surgery within the last 6 months; * Systemic thromboembolic event less than 6 months ago; * Pulmonary embolism less than 6 months ago or pulmonary hypertension requiring specific treatment; * Inability to read independently * Vulnerable patient: minor, patient under curatorship or guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Persistent atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Persistent atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nice

    RECRUITING

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.